Dr. Bryan A. Faller
Claim this profileCrossroads Cancer Center
Expert in Skin Cancer
Expert in Cancer
235 reported clinical trials
294 drugs studied
Area of expertise
1Skin Cancer
Global LeaderStage IV
Stage III
Stage I
2Cancer
Global LeaderStage IV
Stage III
Stage I
Affiliated Hospitals
Clinical Trials Bryan A. Faller is currently running
Surgery and Radiation vs. Radiation Alone
for Brain Cancer
This phase III trial compares the addition of stereotactic radiosurgery before or after surgery in treating patients with cancer that has spread to the brain (brain metastases). Stereotactic radiosurgery is a type of radiation therapy that delivers a high dose of radiation only to the small areas of cancer in the brain and avoids the surrounding normal brain tissue. Surgery and radiation may stop the tumor from growing for a few months or longer and may reduce symptoms of brain metastases.
Recruiting2 awards Phase 3
Chemotherapy + Immunotherapy
for Esophageal and Gastric Cancer
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting2 awards Phase 32 criteria
More about Bryan A. Faller
Clinical Trial Related6 years of experience running clinical trials · Led 235 trials as a Principal Investigator · 132 Active Clinical TrialsTreatments Bryan A. Faller has experience with
- Nivolumab
- Pembrolizumab
- Carboplatin
- Cisplatin
- Paclitaxel
- Atezolizumab
Breakdown of trials Bryan A. Faller has run
Skin Cancer
Cancer
Lung Cancer
Breast Cancer
Gastroesophageal Junction Adenocarcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Bryan A. Faller specialize in?
Bryan A. Faller focuses on Skin Cancer and Cancer. In particular, much of their work with Skin Cancer has involved Stage IV patients, or patients who are Stage III.
Is Bryan A. Faller currently recruiting for clinical trials?
Yes, Bryan A. Faller is currently recruiting for 125 clinical trials in Effingham Illinois. If you're interested in participating, you should apply.
Are there any treatments that Bryan A. Faller has studied deeply?
Yes, Bryan A. Faller has studied treatments such as Nivolumab, Pembrolizumab, Carboplatin.
What is the best way to schedule an appointment with Bryan A. Faller?
Apply for one of the trials that Bryan A. Faller is conducting.
What is the office address of Bryan A. Faller?
The office of Bryan A. Faller is located at: Crossroads Cancer Center, Effingham, Illinois 62401 United States. This is the address for their practice at the Crossroads Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.